Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI

Several respiratory pathogens are responsible for influenza-like illness (ILI) and severe respiratory infections (SARI), among which human respiratory syncytial virus (hRSV) represents one of the most common aetiologies. We analysed the hRSV prevalence among subjects with ILI or SARI during the five...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fabio Tramuto, Carmelo Massimo Maida, Daniela Di Naro, Giulia Randazzo, Francesco Vitale, Vincenzo Restivo, Claudio Costantino, Emanuele Amodio, Alessandra Casuccio, Giorgio Graziano, Palmira Immordino, Walter Mazzucco
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	respiratory syncytial virus molecular surveillance risk factors vaccination community hospitalization Medicine R
Acceso en línea:	https://doaj.org/article/9f50be60d8b54e82a07aa68c4b3dd611
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9f50be60d8b54e82a07aa68c4b3dd611
record_format	dspace
spelling	oai:doaj.org-article:9f50be60d8b54e82a07aa68c4b3dd6112021-11-25T19:11:24ZRespiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI10.3390/vaccines91113342076-393Xhttps://doaj.org/article/9f50be60d8b54e82a07aa68c4b3dd6112021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1334https://doaj.org/toc/2076-393XSeveral respiratory pathogens are responsible for influenza-like illness (ILI) and severe respiratory infections (SARI), among which human respiratory syncytial virus (hRSV) represents one of the most common aetiologies. We analysed the hRSV prevalence among subjects with ILI or SARI during the five influenza seasons before the emergence of SARS-CoV-2 epidemic in Sicily (Italy). Respiratory specimens from ILI outpatients and SARI inpatients were collected in the framework of the Italian Network for the Influenza Surveillance and molecularly tested for hRSV-A and hRSV-B. Overall, 8.1% of patients resulted positive for hRSV. Prevalence peaked in the age-groups <5 years old (range: 17.6–19.1%) and ≥50 years old (range: 4.8–5.1%). While the two subgroups co-circulated throughout the study period, hRSV-B was slightly predominant over hRSV-A, except for the season 2019–2020 when hRSV-A strongly prevailed (82.9%). In the community setting, the distribution of hRSV subgroups was balanced (47.8% vs. 49.7% for hRSV-A and hRSV-B, respectively), while most infections identified in the hospital setting were caused by hRSV-B (69.5%); also, this latter one was more represented among hRSV cases with underlying diseases, as well as among those who developed a respiratory complication. The molecular surveillance of hRSV infections may provide a valuable insight into the epidemiological features of ILI/SARI. Our findings add new evidence to the existing knowledge on viral aetiology of ILI and SARI in support of public health strategies and may help to define high-risk categories that could benefit from currently available and future vaccines.Fabio TramutoCarmelo Massimo MaidaDaniela Di NaroGiulia RandazzoFrancesco VitaleVincenzo RestivoClaudio CostantinoEmanuele AmodioAlessandra CasuccioGiorgio GrazianoPalmira ImmordinoWalter MazzuccoMDPI AGarticlerespiratory syncytial virusmolecular surveillancerisk factorsvaccinationcommunityhospitalizationMedicineRENVaccines, Vol 9, Iss 1334, p 1334 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	respiratory syncytial virus molecular surveillance risk factors vaccination community hospitalization Medicine R
spellingShingle	respiratory syncytial virus molecular surveillance risk factors vaccination community hospitalization Medicine R Fabio Tramuto Carmelo Massimo Maida Daniela Di Naro Giulia Randazzo Francesco Vitale Vincenzo Restivo Claudio Costantino Emanuele Amodio Alessandra Casuccio Giorgio Graziano Palmira Immordino Walter Mazzucco Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI
description	Several respiratory pathogens are responsible for influenza-like illness (ILI) and severe respiratory infections (SARI), among which human respiratory syncytial virus (hRSV) represents one of the most common aetiologies. We analysed the hRSV prevalence among subjects with ILI or SARI during the five influenza seasons before the emergence of SARS-CoV-2 epidemic in Sicily (Italy). Respiratory specimens from ILI outpatients and SARI inpatients were collected in the framework of the Italian Network for the Influenza Surveillance and molecularly tested for hRSV-A and hRSV-B. Overall, 8.1% of patients resulted positive for hRSV. Prevalence peaked in the age-groups <5 years old (range: 17.6–19.1%) and ≥50 years old (range: 4.8–5.1%). While the two subgroups co-circulated throughout the study period, hRSV-B was slightly predominant over hRSV-A, except for the season 2019–2020 when hRSV-A strongly prevailed (82.9%). In the community setting, the distribution of hRSV subgroups was balanced (47.8% vs. 49.7% for hRSV-A and hRSV-B, respectively), while most infections identified in the hospital setting were caused by hRSV-B (69.5%); also, this latter one was more represented among hRSV cases with underlying diseases, as well as among those who developed a respiratory complication. The molecular surveillance of hRSV infections may provide a valuable insight into the epidemiological features of ILI/SARI. Our findings add new evidence to the existing knowledge on viral aetiology of ILI and SARI in support of public health strategies and may help to define high-risk categories that could benefit from currently available and future vaccines.
format	article
author	Fabio Tramuto Carmelo Massimo Maida Daniela Di Naro Giulia Randazzo Francesco Vitale Vincenzo Restivo Claudio Costantino Emanuele Amodio Alessandra Casuccio Giorgio Graziano Palmira Immordino Walter Mazzucco
author_facet	Fabio Tramuto Carmelo Massimo Maida Daniela Di Naro Giulia Randazzo Francesco Vitale Vincenzo Restivo Claudio Costantino Emanuele Amodio Alessandra Casuccio Giorgio Graziano Palmira Immordino Walter Mazzucco
author_sort	Fabio Tramuto
title	Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI
title_short	Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI
title_full	Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI
title_fullStr	Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI
title_full_unstemmed	Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI
title_sort	respiratory syncytial virus: new challenges for molecular epidemiology surveillance and vaccination strategy in patients with ili/sari
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/9f50be60d8b54e82a07aa68c4b3dd611
work_keys_str_mv	AT fabiotramuto respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT carmelomassimomaida respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT danieladinaro respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT giuliarandazzo respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT francescovitale respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT vincenzorestivo respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT claudiocostantino respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT emanueleamodio respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT alessandracasuccio respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT giorgiograziano respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT palmiraimmordino respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari AT waltermazzucco respiratorysyncytialvirusnewchallengesformolecularepidemiologysurveillanceandvaccinationstrategyinpatientswithilisari
_version_	1718410172756393984

Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI

Ejemplares similares